' 
![]()
SCIENTIFIC SCORE
Possibly Effective
Based on 51 Researches
7
USERS' SCORE
Good
Based on 3 Reviews
8.6
Supplement Facts
Serving Size: 1 Soft Gel
Amount Per Serving
%DV
Calories
5
Total Fat
0.5 g
1%**
Cholesterol
<5mg
<2%
Vitamin A (from cod live oil and retinyl palmitate)
27 mcg RAE
3%
Vitamin D (as cholecalciferol) (from cod liver oil and cholecalciferol concentrate)
100 mcg (4,000 IU)
500%
Vitamin E (as d-alpha tocopherol)
0.67 mg
4%
Norwegian Cod Liver Oil
500 mg
†
Total Omega-3 fatty Acids☆
115 mg
†
DHA (Docosahexaenoic Acid)☆
50 mg
†
EPA (Eicosapentaenoic Acid)☆
42 mg
†
Top Medical Research Studies
8
Eicosapentaenoic acid reduces MS symptoms
Eicosapentaenoic acid (EPA) induces peroxisome proliferator-activated receptors and ameliorates experimental autoimmune encephalomyelitis.
Direct evaluation of EPA's effectiveness
We explored the therapeutic effects of eicosapentaenoic acid (EPA) in tackling multiple sclerosis through a study involving mice with experimental autoimmune encephalomyelitis (EAE). The mice were given diets enriched with or without EPA. Remarkably, the mice that received the EPA-infused diet displayed significantly lower clinical scores compared to those that did not.
Furthermore, we observed that the production of inflammatory markers like IFN-γ and IL-17 was notably reduced in the EPA-treated mice. This reduction is particularly important, as these markers are associated with the progression of multiple sclerosis. Additionally, there was an enhancement in the expression levels of peroxisome proliferator-activated receptors within the CD4T cells infiltrating the central nervous system.
These findings suggest that EPA could serve as a promising new approach to therapy for multiple sclerosis, showcasing its potential in reducing inflammation and improving clinical outcomes in those affected by this condition.
Furthermore, we observed that the production of inflammatory markers like IFN-γ and IL-17 was notably reduced in the EPA-treated mice. This reduction is particularly important, as these markers are associated with the progression of multiple sclerosis. Additionally, there was an enhancement in the expression levels of peroxisome proliferator-activated receptors within the CD4T cells infiltrating the central nervous system.
These findings suggest that EPA could serve as a promising new approach to therapy for multiple sclerosis, showcasing its potential in reducing inflammation and improving clinical outcomes in those affected by this condition.
Read More
9
Cod liver oil may reduce MS risk
Timing of use of cod liver oil, a vitamin D source, and multiple sclerosis risk: The EnvIMS study.
High relevance in vitamin D research
We investigated the potential link between cod liver oil, a common source of vitamin D, and the risk of developing multiple sclerosis (MS). Our study involved a robust methodology, gathering data from 953 MS patients and 1717 control participants who reported their cod liver oil consumption from childhood through adulthood.
One of our key findings highlighted that individuals who took cod liver oil during their teenage years—specifically ages 13 to 18—had a noticeably reduced risk of MS. The odds ratio was 0.67, suggesting that this specific timeframe is crucial for vitamin D intake's protective effect against the disease. Interestingly, we didn’t observe any significant correlation between MS risk and the use of cod liver oil in early childhood, meaning that the timing of consumption seems important.
Moreover, we noticed an intriguing dose-response relationship: the more vitamin D3 one consumed during adolescence, the lower the risk of MS appeared to be. The sweetest spot seems to be a daily intake of 600-800 IU, which correlated to a significantly lower MS risk.
Overall, these findings strengthen the idea that low vitamin D levels might be a significant risk factor for MS, with particular emphasis on adolescence as a critical period for preventative measures.
One of our key findings highlighted that individuals who took cod liver oil during their teenage years—specifically ages 13 to 18—had a noticeably reduced risk of MS. The odds ratio was 0.67, suggesting that this specific timeframe is crucial for vitamin D intake's protective effect against the disease. Interestingly, we didn’t observe any significant correlation between MS risk and the use of cod liver oil in early childhood, meaning that the timing of consumption seems important.
Moreover, we noticed an intriguing dose-response relationship: the more vitamin D3 one consumed during adolescence, the lower the risk of MS appeared to be. The sweetest spot seems to be a daily intake of 600-800 IU, which correlated to a significantly lower MS risk.
Overall, these findings strengthen the idea that low vitamin D levels might be a significant risk factor for MS, with particular emphasis on adolescence as a critical period for preventative measures.
Read More
9
Pistachio oil shows promise in MS
The therapeutic effect of PEGlated nanoliposome of pistachio unsaturated oils and its efficacy to attenuate inflammation in multiple sclerosis: A randomized, double-blind, placebo-controlled clinical trial phase I.
Relevant to MS treatment research
We aimed to evaluate how docosahexaenoic acid, particularly through the treatment of PEGlated nanoliposomes of pistachio unsaturated oils (PEGNLPUOs), affects inflammation in multiple sclerosis (MS).
This investigation was rigorously designed as a randomized, double-blind, placebo-controlled trial, ensuring the reliability of our findings. We observed significant changes in the levels of docosahexaenoic and eicosapentaenoic acid among MS patients treated with PEGNLPUOs.
Moreover, we found a notable decrease in matrix metallopeptidase-9 levels, which is important in regulating inflammation. The cytokine profile showed a tilt towards a Th2-biased response, indicating a reduction in inflammatory activity following treatment.
In summary, our findings indicated a reduction in the number of relapses, improved disability scores, and fewer T2 lesions in patients receiving PEGNLPUOs. Through this study, we demonstrated a promising therapeutic avenue for alleviating inflammation associated with multiple sclerosis using docosahexaenoic acid-based treatments.
This investigation was rigorously designed as a randomized, double-blind, placebo-controlled trial, ensuring the reliability of our findings. We observed significant changes in the levels of docosahexaenoic and eicosapentaenoic acid among MS patients treated with PEGNLPUOs.
Moreover, we found a notable decrease in matrix metallopeptidase-9 levels, which is important in regulating inflammation. The cytokine profile showed a tilt towards a Th2-biased response, indicating a reduction in inflammatory activity following treatment.
In summary, our findings indicated a reduction in the number of relapses, improved disability scores, and fewer T2 lesions in patients receiving PEGNLPUOs. Through this study, we demonstrated a promising therapeutic avenue for alleviating inflammation associated with multiple sclerosis using docosahexaenoic acid-based treatments.
Read More
Most Useful Reviews
9.5
Increased energy levels
I’m very pleased! My doctor in Finland recommended this product a year ago for my multiple sclerosis. Since then, I've taken one capsule daily, and I feel full of energy, no longer tired as I used to be. Remarkably, my pain has eased and I haven’t had flu all year! My migraines have also vanished; previously, I consumed medication every week. I’m truly satisfied and grateful for this change!
Read More
8.8
Reduced pain medication
The pains and vigour I experience with multiple sclerosis have improved significantly since I began taking Carlsons D3-vitamin. After a car accident a few years ago, I underwent back surgery, and the stiffness led to chronic pain. However, this vitamin has transformed my wellness, allowing me to rarely need pain pills now. I’m very grateful, feeling energised with only 7 hours of sleep, compared to the 10-12 hours I used to need. I highly recommend consulting a knowledgeable doctor who appreciates such remedies. Thank you!
Read More
8.8
Improved mood and focus
I've just started taking these Vitamin D3 + Omega-3 soft gels and they are a complete game-changer. Each capsule offers 2,000 IU of Vitamin D3, which I need since I spend most of my time indoors, along with 115 mg of Omega-3s for heart and brain health. The pleasant lemon flavour ensures no fishy aftertaste. I’ve noticed a significant boost in mood and energy, better concentration, and even my skin looks better. I highly recommend these if you want the benefits of both supplements without taking multiple pills.
Read More
Medical Researches
SCIENTIFIC SCORE
Possibly Effective
Based on 51 Researches
7
9
Vitamin D may help MS treatment
Targeting aryl hydrocarbon receptor functionally restores tolerogenic dendritic cells derived from patients with multiple sclerosis.
Focus on combined therapies
We evaluated how vitamin D affects multiple sclerosis (MS) by exploring the properties of immune cells in treatment-naive MS patients compared to healthy donors. Our research revealed that patients’ immune cells had heightened proinflammatory features, particularly related to key pathways involving the aryl hydrocarbon receptor (AhR) and NF-κB. This imbalance may contribute to the difficulties in managing MS effectively.
We discovered that dendritic cells derived from MS patients showed reduced tolerogenic capabilities. However, when we applied vitamin D3 and directly activated the AhR, we were able to restore these properties. Furthermore, combining vitamin D3 with a drug known as dimethyl fumarate (DMF) not only enhanced the tolerogenic effects but also provided a more effective treatment option in experiments on mice.
Our findings suggest that a combined therapy utilizing DMF and vitamin D3-tolerogenic dendritic cells has great potential in improving treatment for MS. However, it is worth noting that the analysis focuses on the combination therapy rather than isolating the effects of vitamin D alone.
We discovered that dendritic cells derived from MS patients showed reduced tolerogenic capabilities. However, when we applied vitamin D3 and directly activated the AhR, we were able to restore these properties. Furthermore, combining vitamin D3 with a drug known as dimethyl fumarate (DMF) not only enhanced the tolerogenic effects but also provided a more effective treatment option in experiments on mice.
Our findings suggest that a combined therapy utilizing DMF and vitamin D3-tolerogenic dendritic cells has great potential in improving treatment for MS. However, it is worth noting that the analysis focuses on the combination therapy rather than isolating the effects of vitamin D alone.
Read More
9
Cod liver oil may reduce MS risk
Timing of use of cod liver oil, a vitamin D source, and multiple sclerosis risk: The EnvIMS study.
High relevance in vitamin D research
We investigated the potential link between cod liver oil, a common source of vitamin D, and the risk of developing multiple sclerosis (MS). Our study involved a robust methodology, gathering data from 953 MS patients and 1717 control participants who reported their cod liver oil consumption from childhood through adulthood.
One of our key findings highlighted that individuals who took cod liver oil during their teenage years—specifically ages 13 to 18—had a noticeably reduced risk of MS. The odds ratio was 0.67, suggesting that this specific timeframe is crucial for vitamin D intake's protective effect against the disease. Interestingly, we didn’t observe any significant correlation between MS risk and the use of cod liver oil in early childhood, meaning that the timing of consumption seems important.
Moreover, we noticed an intriguing dose-response relationship: the more vitamin D3 one consumed during adolescence, the lower the risk of MS appeared to be. The sweetest spot seems to be a daily intake of 600-800 IU, which correlated to a significantly lower MS risk.
Overall, these findings strengthen the idea that low vitamin D levels might be a significant risk factor for MS, with particular emphasis on adolescence as a critical period for preventative measures.
One of our key findings highlighted that individuals who took cod liver oil during their teenage years—specifically ages 13 to 18—had a noticeably reduced risk of MS. The odds ratio was 0.67, suggesting that this specific timeframe is crucial for vitamin D intake's protective effect against the disease. Interestingly, we didn’t observe any significant correlation between MS risk and the use of cod liver oil in early childhood, meaning that the timing of consumption seems important.
Moreover, we noticed an intriguing dose-response relationship: the more vitamin D3 one consumed during adolescence, the lower the risk of MS appeared to be. The sweetest spot seems to be a daily intake of 600-800 IU, which correlated to a significantly lower MS risk.
Overall, these findings strengthen the idea that low vitamin D levels might be a significant risk factor for MS, with particular emphasis on adolescence as a critical period for preventative measures.
Read More
9
Pistachio oil shows promise in MS
The therapeutic effect of PEGlated nanoliposome of pistachio unsaturated oils and its efficacy to attenuate inflammation in multiple sclerosis: A randomized, double-blind, placebo-controlled clinical trial phase I.
Relevant to MS treatment research
We aimed to evaluate how docosahexaenoic acid, particularly through the treatment of PEGlated nanoliposomes of pistachio unsaturated oils (PEGNLPUOs), affects inflammation in multiple sclerosis (MS).
This investigation was rigorously designed as a randomized, double-blind, placebo-controlled trial, ensuring the reliability of our findings. We observed significant changes in the levels of docosahexaenoic and eicosapentaenoic acid among MS patients treated with PEGNLPUOs.
Moreover, we found a notable decrease in matrix metallopeptidase-9 levels, which is important in regulating inflammation. The cytokine profile showed a tilt towards a Th2-biased response, indicating a reduction in inflammatory activity following treatment.
In summary, our findings indicated a reduction in the number of relapses, improved disability scores, and fewer T2 lesions in patients receiving PEGNLPUOs. Through this study, we demonstrated a promising therapeutic avenue for alleviating inflammation associated with multiple sclerosis using docosahexaenoic acid-based treatments.
This investigation was rigorously designed as a randomized, double-blind, placebo-controlled trial, ensuring the reliability of our findings. We observed significant changes in the levels of docosahexaenoic and eicosapentaenoic acid among MS patients treated with PEGNLPUOs.
Moreover, we found a notable decrease in matrix metallopeptidase-9 levels, which is important in regulating inflammation. The cytokine profile showed a tilt towards a Th2-biased response, indicating a reduction in inflammatory activity following treatment.
In summary, our findings indicated a reduction in the number of relapses, improved disability scores, and fewer T2 lesions in patients receiving PEGNLPUOs. Through this study, we demonstrated a promising therapeutic avenue for alleviating inflammation associated with multiple sclerosis using docosahexaenoic acid-based treatments.
Read More
9
DHA's impact on multiple sclerosis
A Novel Combination of Docosahexaenoic Acid, All-Trans Retinoic Acid, and 1, 25-Dihydroxyvitamin D Reduces T-Bet Gene Expression, Serum Interferon Gamma, and Clinical Scores but Promotes PPARγ Gene Expression in Experimental Autoimmune Encephalomyelitis.
Combination therapy complicates isolation
We aimed to understand how docosahexaenoic acid (DHA) influences multiple sclerosis by exploring its effects in combination with other nutrients. Through a carefully designed study, we assessed the protective benefits of DHA, alongside all-trans retinoic acid (ATRA) and 1,25-dihydroxyvitamin D, on a model of multiple sclerosis known as experimental autoimmune encephalomyelitis (EAE).
The study involved female C57BL/6 mice divided into treated and untreated groups to observe the impact of these nutrients on the disease's progression. The results were striking. We found that when DHA was administered with ATRA and vitamin D, there was a significant reduction in clinical symptoms, and less interferon gamma and T-bet gene expression—key contributors to the inflammatory response observed in multiple sclerosis.
While the combination treatment showed clear benefits, it's important to note that the specific role of DHA on its own was difficult to isolate. The intervention collectively reduced the severity of the disease and inflammation, hinting at its potential for treating similar autoimmune conditions. Overall, our findings suggest that exploring DHA within combined therapies might be a promising pathway for managing multiple sclerosis.
The study involved female C57BL/6 mice divided into treated and untreated groups to observe the impact of these nutrients on the disease's progression. The results were striking. We found that when DHA was administered with ATRA and vitamin D, there was a significant reduction in clinical symptoms, and less interferon gamma and T-bet gene expression—key contributors to the inflammatory response observed in multiple sclerosis.
While the combination treatment showed clear benefits, it's important to note that the specific role of DHA on its own was difficult to isolate. The intervention collectively reduced the severity of the disease and inflammation, hinting at its potential for treating similar autoimmune conditions. Overall, our findings suggest that exploring DHA within combined therapies might be a promising pathway for managing multiple sclerosis.
Read More
9
DHA's role in MS treatment
n-3 PUFA supplementation benefits microglial responses to myelin pathology.
High relevance to multiple sclerosis
We explored the effects of docosahexaenoic acid (DHA), a vital Omega-3 polyunsaturated fatty acid, on multiple sclerosis (MS) and the way it influences microglial responses to myelin damage. By examining both primary cell cultures and using the cuprizone mouse model of MS, we aimed to understand how DHA behaves in conditions mimicking this debilitating disease.
Our findings revealed that DHA, alongside another Omega-3 fatty acid known as eicosapentaenoic acid (EPA), was successful in reducing harmful inflammatory responses in primary microglia when stimulated by interferon-gamma and myelin. These beneficial acids slowed down the release of substances like nitric oxide and tumor necrosis factor-alpha, which can contribute to tissue damage.
In addition, we noted an encouraging increase in myelin phagocytosis, which is a process where microglia clean up dead or damaged myelin. Our in vivo studies showed that supplementing with n-3 PUFAs like DHA could effectively diminish demyelination caused by cuprizone and lead to notable improvements in motor skills and cognitive function. Furthermore, we observed a transition in microglial behavior towards a 'friendly' M2 phenotype, suggesting that these fatty acids play a role in fostering a supportive environment in the brain.
Overall, this research indicates that DHA and other n-3 PUFAs hold promise as potential immunomodulatory agents for managing demyelinating diseases like multiple sclerosis.
Our findings revealed that DHA, alongside another Omega-3 fatty acid known as eicosapentaenoic acid (EPA), was successful in reducing harmful inflammatory responses in primary microglia when stimulated by interferon-gamma and myelin. These beneficial acids slowed down the release of substances like nitric oxide and tumor necrosis factor-alpha, which can contribute to tissue damage.
In addition, we noted an encouraging increase in myelin phagocytosis, which is a process where microglia clean up dead or damaged myelin. Our in vivo studies showed that supplementing with n-3 PUFAs like DHA could effectively diminish demyelination caused by cuprizone and lead to notable improvements in motor skills and cognitive function. Furthermore, we observed a transition in microglial behavior towards a 'friendly' M2 phenotype, suggesting that these fatty acids play a role in fostering a supportive environment in the brain.
Overall, this research indicates that DHA and other n-3 PUFAs hold promise as potential immunomodulatory agents for managing demyelinating diseases like multiple sclerosis.
Read More
User Reviews
USERS' SCORE
Good
Based on 3 Reviews
8.6
9.5
Increased energy levels
I’m very pleased! My doctor in Finland recommended this product a year ago for my multiple sclerosis. Since then, I've taken one capsule daily, and I feel full of energy, no longer tired as I used to be. Remarkably, my pain has eased and I haven’t had flu all year! My migraines have also vanished; previously, I consumed medication every week. I’m truly satisfied and grateful for this change!
Read More
8.8
Reduced pain medication
The pains and vigour I experience with multiple sclerosis have improved significantly since I began taking Carlsons D3-vitamin. After a car accident a few years ago, I underwent back surgery, and the stiffness led to chronic pain. However, this vitamin has transformed my wellness, allowing me to rarely need pain pills now. I’m very grateful, feeling energised with only 7 hours of sleep, compared to the 10-12 hours I used to need. I highly recommend consulting a knowledgeable doctor who appreciates such remedies. Thank you!
Read More
8.8
Improved mood and focus
I've just started taking these Vitamin D3 + Omega-3 soft gels and they are a complete game-changer. Each capsule offers 2,000 IU of Vitamin D3, which I need since I spend most of my time indoors, along with 115 mg of Omega-3s for heart and brain health. The pleasant lemon flavour ensures no fishy aftertaste. I’ve noticed a significant boost in mood and energy, better concentration, and even my skin looks better. I highly recommend these if you want the benefits of both supplements without taking multiple pills.
Read More
